Patient Information

If used during pregnancy, ZEPOSIA® (ozanimod) can harm the unborn baby. Potential risks include loss of the unborn baby and birth defects.

- Do not use ozanimod if you are pregnant or breast-feeding, or could become pregnant and are not using effective birth control.
- Before starting treatment with ozanimod:
 - 1. Your doctor will explain the potential serious risks associated with ozanimod to an unborn baby and will regularly inform you how to

contraception options available to you.

- minimize the risks.
- 2. Your doctor will carry out a pregnancy test and it must be negative. 3. You will need to use effective contraception to avoid becoming pregnant. Talk to your doctor about the most effective

- While you are taking ozanimod and after you stop treatment: 1. You must use effective contraception without interruption while
 - taking ozanimod and for 3 months after you stop taking it. Pregnancy tests will be repeated during treatment. 2. Tell your doctor immediately if you become pregnant or think

planning a pregnancy.

- you may be pregnant whilst taking ozanimod, or for 3 months after you stop taking it. Your doctor will discuss the risk of harmful effects to the baby associated with treatment and ultrasound examinations will be offered if needed. Ozanimod must be stopped during pregnancy.
- 3. If you are planning to get pregnant, talk to your doctor. Your doctor will need to stop your treatment 3 months before

may return. Tell your doctor right away if your disease related symptoms get worse after stopping treatment.

4. If your treatment is stopped, there is a possibility that the disease

- Please see the back of this reminder card for your prescriber's contact
- information

For more information about the effects and side effects of ozanimod.

please refer to the Patient/Caregiver Guide for ozanimod.

I have been prescribed ZEPOSIA®.	·	ZEPOSIA® (ozanimod)
Important Contact Information		<u>(2288</u>)
My healthcare professional who prescribed ZEPOSIA®:		Pregnancy Reminder Card
N	1	

Name

(For women of childbearing potential) Office phone number:

Institution address :

This document has been approved by HSA on 17/May/2023

BMS Document Number:

2084-SG-2200002

Bristol Myers Squibb